This study aimed to compare Likert scores with radical prostatectomy specimens. This study examined 443 men with validated pre-biopsy magnetic resonance imaging results and used cross-tabulation and chi-square significance testing with National Comprehensive Cancer Network risk categories. The mean prostate-specific antigen (PSA) was 10, and the mean age was 64 years. Comparing Likert III to Likert V and Likert IV to Likert V, both (each p=0.02) were significantly associated with higher prostate cancer risk groups, but Likert III versus Likert IV was not (p=0.1). Within the subgroup PSA density (PSAD) 0.15 (n=281; p=0.045 III vs. IV only and p=0.055 overall). Within the subgroup age 60 (n=339) this significant difference was lost (p=0.34). Further subgroup analysis within Likert III (n=86) found that men <60 (n=22) had neither high-grade (G3 or G4 or G5) nor very high-risk disease. There were only two high-risk cases, both of which were G2T3a (2/22; 10%). In men with Likert III and PSAD <0.15 (n=31), there were seven high-risk and two very high-risk cases (9/31; 25%). This difference was not significant (p=0.31) With these two findings, we recommend that men <60 with Likert III can be counselled like men with Likert III and PSAD <0.15, that they are unlikely to have unfavourable or high-risk disease and that they may wish to avoid biopsy or treatment. Level 1b.